<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The risk of developing a range of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> is increased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and may be influenced by <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering therapies </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the risk of development of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> in relation to treatment with oral agents, human insulin and insulin analogues </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This was a retrospective cohort study of people treated in UK general practices </plain></SENT>
<SENT sid="3" pm="."><plain>Those included in the analysis developed <z:mp ids='MP_0002055'>diabetes</z:mp> &gt;40 years of age, and started treatment with oral agents or insulin after 2000 </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 62,809 patients were divided into four groups according to whether they received monotherapy with <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, combined therapy (<z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>), or insulin </plain></SENT>
<SENT sid="5" pm="."><plain>Insulin users were grouped according to treatment with insulin glargine, long-acting human insulin, biphasic analogue and human biphasic insulin </plain></SENT>
<SENT sid="6" pm="."><plain>The outcome measures were progression to any <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumour</z:e>, or <z:e sem="disease" ids="C0006142,C0678222" disease_type="Neoplastic Process" abbrv="">cancer of the breast</z:e>, colon, pancreas or prostate </plain></SENT>
<SENT sid="7" pm="."><plain>Confounding factors were accounted for using Cox proportional hazards models </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> monotherapy carried the lowest risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In comparison, the adjusted HR was 1.08 (95% CI 0.96-1.21) for <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, 1.36 (95% CI 1.19-1.54) for <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> monotherapy, and 1.42 (95% CI 1.27-1.60) for insulin-based regimens </plain></SENT>
<SENT sid="10" pm="."><plain>Adding <z:chebi fb="0" ids="6801">metformin</z:chebi> to insulin reduced progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (HR 0.54, 95% CI 0.43-0.66) </plain></SENT>
<SENT sid="11" pm="."><plain>The risk for those on basal human insulin alone vs insulin glargine alone was 1.24 (95% CI 0.90-1.70) </plain></SENT>
<SENT sid="12" pm="."><plain>Compared with <z:chebi fb="0" ids="6801">metformin</z:chebi>, insulin therapy increased the risk of colorectal (HR 1.69, 95% CI 1.23-2.33) or <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> (HR 4.63, 95% CI 2.64-8.10), but did not influence the risk of breast or <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain><z:chebi fb="0" ids="26831">Sulfonylureas</z:chebi> were associated with a similar pattern of risk as insulin </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS/INTERPRETATION: Those on insulin or insulin secretagogues were more likely to develop solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> than those on <z:chebi fb="0" ids="6801">metformin</z:chebi>, and combination with <z:chebi fb="0" ids="6801">metformin</z:chebi> abolished most of this excess risk </plain></SENT>
<SENT sid="15" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> use was associated with lower risk of <z:e sem="disease" ids="C0007102" disease_type="Neoplastic Process" abbrv="">cancer of the colon</z:e> or pancreas, but did not affect the risk of breast or <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>Use of insulin analogues was not associated with increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk as compared with human insulin </plain></SENT>
</text></document>